Abstract:AbstractThe BET family member BRD4 is a bromodomain-containing protein that plays a vital role in driving oncogene expression. Given their pivotal role in regulating oncogenic networks in various cancer types, BET inhibitors (BETi) have been developed, but the clinical application has been impeded by dose-limiting toxicity and resistance. Understanding the mechanisms of BRD4 activity and identifying predictive biomarkers could facilitate the successful clinical use of BETis. Herein, we show that KDM5C and BRD4 cooperate to sustain tumor cell growth. Mechanistically, KDM5C interacted with BRD4 and stimulated BRD4 enhancer recruitment. Moreover, binding of the BRD4 C-terminus to KDM5C stimulated the H3K4 demethylase activity of KDM5C. The abundance of both KDM5C-associated BRD4 and H3K4me1/3 determined the transcriptional activation of many oncogenes. Notably, depletion or pharmacologic degradation of KDM5C dramatically reduced BRD4 chromatin enrichment and significantly increased BETi efficacy across multiple cancer types in both tumor cell lines and patient-derived organoid models. Furthermore, targeting KDM5C in combination with BETi suppressed tumor growth in vivo in a xenograft mouse model. Collectively, this work reveals a KDM5C-mediated mechanism by which BRD4 regulates transcription, providing a rationale for incorporating BETi into combination therapies with KDM5C inhibitors to enhance treatment efficacy.Significance:BRD4 is recruited to enhancers in a bromodomain-independent manner by binding KDM5C and stimulates KDM5C H3K4 demethylase activity, leading to synergistic effects of BET and KDM5C inhibitor combinations in cancer.

BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones

BRD4: a general regulator of transcription elongation

BRD2 Interconnects with BRD3 to Facilitate Pol II Transcription Initiation and Elongation to Prime Promoters for Cell Differentiation.

Structural Basis and Binding Properties of the Second Bromodomain of Brd4 with Acetylated Histone Tails.

BRD4 phosphorylation regulates the structure of chromatin nanodomains

Data from KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity

KDM5C-mediated recruitment of BRD4 to chromatin regulates enhancer activation and BET inhibitor sensitivity

Drug Discovery Targeting Bromodomain-Containing Protein 4

A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer

Supplementary Data Figure S8 from KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity

Supplementary Data Figure S5 from KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity

BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis

Supplementary Data Figure S9 from KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity

The mechanisms behind the therapeutic activity of BET bromodomain inhibition

Signal-induced Brd4 Release from Chromatin is Essential for Its Role Transition from Chromatin Targeting to Transcriptional Regulation

Roles of the BRD4 Short Isoform in Phase Separation and Active Gene Transcription

Supplementary Data Figure S1 from KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity

BRD4 interacts with PML/RARα in acute promyelocytic leukemia

Supplementary Data Figure S7 from KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity

Supplementary Data Figure S3 from KDM5C-Mediated Recruitment of BRD4 to Chromatin Regulates Enhancer Activation and BET Inhibitor Sensitivity